Home › Merck Enhances Immuno-Oncology Portfolio with Acquisition of cCAM Biotherapeutics
 

Keywords :   


Merck Enhances Immuno-Oncology Portfolio with Acquisition of cCAM Biotherapeutics

2015-07-28 12:45:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. & MISGAV, Israel KENILWORTH, N.J. & MISGAV, Israel--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and cCAM Biotherapeutics announced today that the companies have signed a definitive agreement under which Merck will acquire cCAM Biotherapeutics, a privately held biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies. Language: English Contact: Merck Media Relations:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325orMerck Investor Relations:Justin Holko, 908-740-1879orcCAM Investor/Media Relations:Tsipi Haitovsky, +972-525-989892 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: portfolio acquisition enhances merck

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.07Atlantic Tropical Weather Outlook
05.07Eastern North Pacific Tropical Weather Outlook
05.07Samsung expects profits to jump by more than 1,400%
05.07Hurricane Beryl Graphics
05.07Hurricane Beryl Forecast Discussion Number 26
05.07Hurricane Beryl Wind Speed Probabilities Number 26
05.07Hurricane Beryl Forecast Advisory Number 26
05.07Hurricane Beryl Public Advisory Number 26
More »